Related Experiment Video

Updated: May 4, 2026

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

16.1K

The STAT3-Ser/Hes3 signaling axis in cancer

Steven W Poser1, Deric M Park2, Andreas Androutsellis-Theotokis3

  • 1Innate Repair Laboratory, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität, Dresden, Fetscherstrasse 74, 01307 Dresden, Germany.

Frontiers in Bioscience (Landmark Edition)
|January 7, 2014
PubMed

Insights

Cancer stem cells possess unique plasticity, utilizing diverse signaling pathways like JAK/STAT for regeneration. Understanding this adaptability is key to developing novel cancer therapies that overcome treatment resistance.

Area of Science:

  • Oncology
  • Stem Cell Biology
  • Molecular Medicine

Background:

  • Cancer stem cells (CSCs) are crucial for tumor regeneration and treatment resistance.
  • Current therapies often fail to eradicate CSCs due to unidentified molecular mechanisms.
  • Recent research highlights the plasticity of neural stem cells' signaling pathways.

Purpose of the Study:

  • To explore the signaling pathway plasticity in cancer stem cells.
  • To identify novel molecular mechanisms underlying CSC regenerative capacity.
  • To inform the development of more effective anti-cancer treatment strategies.

Main Methods:

  • Investigating the JAK/STAT signaling pathway in CSCs.
  • Analyzing the non-canonical STAT3-Ser/Hes3 signaling axis.
  • Comparing signaling pathway utilization across different tumor cell types.

Main Results:

  • CSCs exhibit remarkable plasticity, employing distinct and opposing signaling pathways for growth.
  • The JAK/STAT and non-canonical STAT3-Ser/Hes3 pathways are utilized by tumorigenic cells.
  • This plasticity may extend beyond CSCs, blurring cell type distinctions within tumors.

Conclusions:

  • Inhibiting one signaling pathway in cancer may inadvertently activate alternative pro-growth pathways.
  • Targeting CSC plasticity offers a conceptually novel approach to anti-cancer drug discovery.
  • Understanding pathway redundancy is critical for overcoming therapeutic resistance in cancer.

More Related Videos

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells09:32

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells

Published on: February 27, 2020

8.4K
Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

1.1K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K